Abstract：
UNASSIGNED: Acute promyelocytic leukemia (APL) is a distinct form of acute myeloid leukemia characterized by the presence of t(15;17)(q24;21) and the PML:RARA gene fusion. Frontline use of intravenous arsenic trioxide (i.v.-ATO) and all-trans retinoic acid (ATRA) has vastly improved cure rates in APL. Researchers in Hong Kong invented the oral formulation of ATO (oral-ATO) and have confirmed a bioavailability comparable to i.v.-ATO. A plethora of studies have confirmed the safety and efficacy of oral-ATO-based regimens in the frontline and relapsed setting.
UNASSIGNED: Aspects on the development of oral-ATO-based regimens for APL in the frontline and relapsed setting are discussed. The short-term and long-term safety and efficacy of oral-ATO-based regimens are discussed. The frontline use of oral-ATO in combination with ATRA and ascorbic acid (AAA) induction in a \'chemotherapy-free\' is highlighted.
UNASSIGNED: Current and ongoing data on the use of oral-ATO-based regimens in APL support the use of oral-ATO as an alternative to i.v.-ATO allowing a more convenient and economical approach to the management of APL.
UNASSIGNED: Aspects on the development of oral-ATO-based regimens for APL in the frontline and relapsed setting are discussed. The short-term and long-term safety and efficacy of oral-ATO-based regimens are discussed. The frontline use of oral-ATO in combination with ATRA and ascorbic acid (AAA) induction in a \'chemotherapy-free\' is highlighted.
UNASSIGNED: Current and ongoing data on the use of oral-ATO-based regimens in APL support the use of oral-ATO as an alternative to i.v.-ATO allowing a more convenient and economical approach to the management of APL.
摘要：
急性早幼粒细胞白血病(APL)是一种不同形式的急性髓性白血病,其特征在于存在t(15;17)(q24;21)和PML:RARA基因融合。静脉内使用三氧化二砷（i.v.-ATO）和全反式视黄酸（ATRA）的前线大大提高了APL的治愈率。香港的研究人员发明了ATO（口服ATO）的口服制剂，并已证实其生物利用度可与i.v.ATO相媲美。大量研究证实了基于口服ATO的方案在一线和复发环境中的安全性和有效性。
■讨论了在前线和复发环境中基于口服ATO的APL方案的发展方面。讨论了基于口服ATO的方案的短期和长期安全性和有效性。强调了口服ATO联合ATRA和抗坏血酸（AAA）诱导在“无化疗”中的一线使用。
■关于在APL中使用基于口服ATO的方案的当前和持续数据支持使用口服ATO作为i.v.ATO的替代方案，从而允许更方便和经济的方法来管理APL。
■讨论了在前线和复发环境中基于口服ATO的APL方案的发展方面。讨论了基于口服ATO的方案的短期和长期安全性和有效性。强调了口服ATO联合ATRA和抗坏血酸（AAA）诱导在“无化疗”中的一线使用。
■关于在APL中使用基于口服ATO的方案的当前和持续数据支持使用口服ATO作为i.v.ATO的替代方案，从而允许更方便和经济的方法来管理APL。
